SHPH
Shuttle Pharm (SHPH)
NASDAQ
$3.82-$0.02 (-0.65%)
Price as of Jun 23, 2026 7:58 PM EDT
  • $2.1M
    Market Cap
  • -89.96%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 50
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

E.F. Hutton & Co. Serves as Exclusive M&A Advisor and Placement Agent on Completed Shuttle Pharmaceuticals–United Dogecoin Merger to Create the Largest Public Dogecoin Miner

E.F. Hutton & Co. announced it served as exclusive M&A advisor and placement agent for Shuttle Pharmaceuticals Holdings' acquisition of United Dogecoin Inc., creating one of the largest publicly traded Dogecoin mining platforms. The transaction included a $9.6 million PIPE financing to support mining operations expansion with next-generation equipment.

05/07/2026, 2:02 PM • Benzinga

Shuttle Executes LOI with Molecule.ai

Shuttle Pharmaceuticals has signed a non-binding letter of intent to acquire Molecule.ai, an AI-driven drug discovery platform, for $10 million. The acquisition aims to leverage advanced machine learning models to accelerate pharmaceutical research and development.

10/10/2025, 10:20 AM • Benzinga

Peers

Statistics

More
Day Range
$3.43
$4.00
$3.84
1-Year Range
$0.45
$4.76
$3.84
Latest Close$3.84
Change
+$0.33 (+8.46%)
Volume75,507
Market Cap$2.1M
Shares Outstanding585,129
P/E (TTM)-0.02
Diluted EPS (TTM)-$142.71
Enterprise Value$1.8M

Information as of 06/23/2026

Company Profile

SHUTTLE PHARMACEUTICALS HOLDINGS INC
SHUTTLE PHARMACEUTICALS HOLDINGS INC
https://www.shuttlepharma.com
$2.1M
Market Cap
-$6.1M
Net Income
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
401 Professional Drive, Gaithersburg, MD, United States, 20879
240 403 4212

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.

Key Executives

  • Michael Vander Hoek
  • Christopher Robert Cooper
  • Tyvin A. Rich
  • Yuying Liang
  • Milton Brown

Current Ownership Distribution

  • Insiders2.7M (57.94%)
  • Institutions1.5M (31.44%)
  • Mutual Funds496,341 (10.62%)
  • Other0 (0.00%)